DILIsym Services Inc. (DSS), a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical efficacy and safety, today announced that it is developing a new component for a QSP model focused on treating heart failure, such as can occur after myocardial infarction. As with other QSP efforts by the company, the development of this new QSP software component is being sponsored by a large pharmaceutical company partner and will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.
This new venture represents the company’s first project focused on QSP for heart failure. DSS expects the resulting IP to enable a pipeline of heart failure-related consulting and licensing revenue in the future, expanding the company’s addressable market. More importantly, the project illustrates the willingness of DSS to partner with its clients to provide custom solutions to their modeling and simulation needs in the areas of both efficacy and safety.
Scott Siler, Chief Scientific Officer of DSS, noted: “This QSP modeling effort builds on our existing competencies in developing models of fibrosis and companion pathophysiologies. Simulating the mechanisms contributing to the development of cardiac fibrosis and its contributions to heart failure will enable us to support the pharmaceutical industry in the development of therapeutics to treat heart failure by predicting efficacy before real-world patients are administered potential drugs.”
Brett Howell, President of DSS, added: “We are well suited to serve the full spectrum of our clients’ QSP needs, such as the development of a custom heart failure-related application in this case. The pharmaceutical industry’s use of QSP modeling approaches to improve development decision making and outcomes is increasing rapidly. Building upon our success in developing DILIsym®, the industry standard for liver safety modeling, we have applied our QSP expertise in an expanding array of therapeutic areas including NASH, pulmonary fibrosis, and now heart failure.”